Neurological symptoms and comorbidity profile of hospitalized patients with COVID-19

Abstract

Background The neurological manifestations in COVID-19 adversely impact acute illness and post-disease quality of life. Limited data exist regarding the association of neurological symptoms and comorbid individuals.

Objective To assess neurological symptoms in hospitalized patients with acute COVID-19 and multicomorbidities.

Methods Between June 2020 and July 2020, inpatients aged 18 or older, with laboratory-confirmed COVID-19, admitted to the Hospital São Paulo (Federal University of São Paulo), a tertiary referral center for high complexity cases, were questioned about neurological symptoms. The Composite Autonomic Symptom Score 31 (COMPASS-31) questionnaire was used. The data were analyzed as a whole and whether subjective olfactory dysfunction was present or not.

Results The mean age of the sample was 55 ± 15.12 years, and 58 patients were male. The neurological symptoms were mostly xerostomia (71%), ageusia/hypogeusia (50%), orthostatic intolerance (49%), anosmia/hyposmia (44%), myalgia (31%), dizziness (24%), xerophthalmia (20%), impaired consciousness (18%), and headache (16%). Furthermore, 91% of the patients had a premorbidity. The 44 patients with subjective olfactory dysfunction were more likely to have hypertension, diabetes, weakness, shortness of breath, ageusia/hypogeusia, dizziness, orthostatic intolerance, and xerophthalmia. The COMPASS-31 score was higher than that of previously published controls (14.85 ± 12.06 vs. 8.9 ± 8.7). The frequency of orthostatic intolerance was 49% in sample and 63.6% in those with subjective olfactory dysfunction (2.9-fold higher risk compared to those without).

Conclusion A total of 80% of inpatients with multimorbidity and acute COVID-19 had neurological symptoms. Chemical sense and autonomic symptoms stood out. Orthostatic intolerance occurred in around two-thirds of the patients with anosmia/hyposmia. Hypertension and diabetes were common, mainly in those with anosmia/hyposmia.

Resumo

Antecedentes As manifestações neurológicas na COVID-19 impactam adversamente na enfermidade aguda e na qualidade de vida após a doença. Dados limitados existem em relação a associação de sintomas neurológicos e indivíduos com comorbidades.

Objetivo Avaliar os sintomas neurológicos em pacientes de hospitalizados com COVID-19 aguda e múltiplas comorbidades.

Métodos Entre junho e julho de 2020, pacientes de hospitais com idade 18 anos ou acima e COVID-19 laboratorialmente confirmada, admitidos no Hospital São Paulo (Universidade Federal de São Paulo), um centro de referência terciário para casos de alta complexidade, foram perguntados sobre sintomas neurológicos. O questionário Pontuação composta de sintoma autonômico (COMPASS-31) foi usado. Os dados foram analisados no geral e se a disfunção olfatória subjetiva estava presente ou não.

Resultados A média de idade da amostra foi 55 ± 15.12 anos. 58 pacientes eram homens. Os sintomas neurológicos foram principalmente xerostomia (71%), ageusia/hipogeusia (50%), intolerância ortostática (49%), anosmia/hiposmia (44%), mialgia (31%), tontura (24%), xeroftalmia (20%), comprometimento na consciência (18%) e cefaleia (16%). Além disso, 91% dos pacientes tinham uma pré-morbidade. Os 44 pacientes com disfunção olfatória tinham maior chance de ter hipertensão, diabetes, fraqueza, falta de ar, ageusia/hipogeusia, tontura, intolerância ortostática e xeroftalmia. A pontuação do COMPASS-31 foi maior do que a de controles previamente publicados (14,85 ± 12,06 vs. 8,9 ± 8,7). A frequência de intolerância ortostática foi 49% na amostra e 63,6% naqueles com disfunção olfatória subjetiva (risco 2.9 vezes maior comparado com os sem).

Conclusão Um total de 80% dos pacientes hospitalizados com múltiplas morbidades e COVID-19 aguda tinham sintomas neurológicos. Os sintomas do sentido químico e autonômicos se destacaram. A intolerância ortostática ocorreu em cerca de dois terços dos pacientes com anosmia/hiposmia. A hipertensão e o diabetes foram comuns, principalmente naqueles com anosmia/hiposmia.

Keywords

COVID-19 - Neurologic Manifestations - Comorbidity - Anosmia - Orthostatic Intolerance - Autonomic Nervous System Diseases

Palavras-chave

COVID-19 - Manifestações Neurológicas - Comorbidade - Anosmia - Intolerância Ortostática - Doenças do Sistema Nervoso Autônomo

Authors' Contributions

RCC, FMC, CAS, JSOA, PAAF, NCJB, VB: research idea and study design, drafting or revision of manuscript; RCC, FMC: data acquisition and interpretation, statistical analysis.

Publikationsverlauf

Eingereicht: 16. Februar 2022

Angenommen: 05. Juni 2022

Artikel online veröffentlicht:
22. März 2023

• References

• 1 Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci 2020; 41 (10) 2657-2669
• 2 Mao L, Jin H, Wang M. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020; 77 (06) 683-690
• 3 Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the Nervous System. Cell 2020; 183 (01) 16-27 .e1
• 4 Sampaio Rocha-Filho PA, Magalhães JE, Fernandes Silva D. et al. Neurological manifestations as prognostic factors in COVID-19: a retrospective cohort study. Acta Neurol Belg 2022; 122 (03) 725-733
• 5 Amanat M, Rezaei N, Roozbeh M. et al. Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study. BMC Neurol 2021; 21 (01) 116
• 6 Rocha-Filho PAS, Magalhães JE. Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia. Cephalalgia 2020; 40 (13) 1443-1451
• 7 Lechien JR, Chiesa-Estomba CM, De Siati DR. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277 (08) 2251-2261
• 8 Baker J, Incognito AV, Wilson RJA, Raj SR. Syncope and silent hypoxemia in COVID-19: Implications for the autonomic field. Auton Neurosci 2021; 235: 102842
• 9 Buoite Stella A, Furlanis G, Frezza NA, Valentinotti R, Ajcevic M, Manganotti P. Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: a prospective multidomain observational study. J Neurol 2022; 269 (02) 587-596
• 10 Dani M, Dirksen A, Taraborrelli P. et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med (Lond) 2021; 21 (01) e63-e67
• 11 Milovanovic B, Djajic V, Bajic D. et al. Assessment of Autonomic Nervous System Dysfunction in the Early Phase of Infection With SARS-CoV-2 Virus. Front Neurosci 2021; 15: 640835
• 12 Eshak N, Abdelnabi M, Ball S. et al. Dysautonomia: An Overlooked Neurological Manifestation in a Critically ill COVID-19 Patient. Am J Med Sci 2020; 360 (04) 427-429
• 13 Atkins JL, Masoli JAH, Delgado J. et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci 2020; 75 (11) 2224-2230
• 14 Vakili K, Fathi M, Hajiesmaeili M. et al. Neurological Symptoms, Comorbidities, and Complications of COVID-19: A Literature Review and Meta-Analysis of Observational Studies. Eur Neurol 2021; 84 (05) 307-324
• 15 Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: Autonomic complications of COVID-19. Auton Neurosci 2021; 235: 102841
• 16 Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 2012; 87 (12) 1196-1201
• 17 Vincent A, Whipple MO, Low PA, Joyner M, Hoskin TL. Patients With Fibromyalgia Have Significant Autonomic Symptoms But Modest Autonomic Dysfunction. PM R 2016; 8 (05) 425-435
• 18 Goldstein DS. The extended autonomic system, dyshomeostasis, and COVID-19. Clin Auton Res 2020; 30 (04) 299-315
• 19 Di Carlo DT, Montemurro N, Petrella G, Siciliano G, Ceravolo R, Perrini P. Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: a systematic review of current literature. J Neurol 2021; 268 (05) 1561-1569
• 20 Soltani S, Tabibzadeh A, Zakeri A. et al. COVID-19 associated central nervous system manifestations, mental and neurological symptoms: a systematic review and meta-analysis. Rev Neurosci 2021; 32 (03) 351-361
• 21 Kleineberg NN, Knauss S, Gülke E. et al; LEOSS Study Group. Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS). Eur J Neurol 2021; 28 (12) 3925-3937
• 22 Buscemi S, Corleo D, Randazzo C. Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity. Adv Exp Med Biol 2021; 1353: 115-129
• 23 Ejaz H, Alsrhani A, Zafar A. et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health 2020; 13 (12) 1833-1839
• 24 Shibata S, Arima H, Asayama K. et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res 2020; 43 (10) 1028-1046
• 25 Zhao Y, Liu Y, Yi F. et al. Type 2 diabetes mellitus impaired nasal immunity and increased the risk of hyposmia in COVID-19 mild pneumonia patients. Int Immunopharmacol 2021; 93: 107406
• 26 Chan JYK, García-Esquinas E, Ko OH, Tong MCF, Lin SY. The Association Between Diabetes and Olfactory Function in Adults. Chem Senses 2017; 43 (01) 59-64
• 27 Kaya KS, Mazı EE, Demir ST, Tetik F, Tuna M, Turgut S. Relationship between progression of type 2 diabetes mellitus and olfactory function. Am J Otolaryngol 2020; 41 (02) 102365
• 28 Greco C, Di Gennaro F, D'Amato C. et al. Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes. Diabet Med 2017; 34 (06) 834-838
• 29 Singh R, Arbaz M, Rai NK, Joshi R. Diagnostic accuracy of composite autonomic symptom scale 31 (COMPASS-31) in early detection of autonomic dysfunction in type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2019; 12: 1735-1742
• 30 Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol 2020; 10 (07) 806-813
• 31 Rodríguez Y, Rojas M, Ramírez-Santana C, Acosta-Ampudia Y, Monsalve DM, Anaya JM. Autonomic symptoms following Zika virus infection. Clin Auton Res 2018; 28 (02) 211-214
• 32 Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm 2021; 18 (04) 508-509
• 33 Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021; 53 (10) 737-754
• 34 Shouman K, Vanichkachorn G, Cheshire WP. et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res 2021; 31 (03) 385-394
• 35 de Freitas RF, Torres SC, Martín-Sánchez FJ, Carbó AV, Lauria G, Nunes JPL. Syncope and COVID-19 disease - A systematic review. Auton Neurosci 2021; 235: 102872
• 36 Canetta C, Accordino S, Buscarini E. et al. Syncope at SARS-CoV-2 onset. Auton Neurosci 2020; 229: 102734
• 37 Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol 2020; 16 (11) 636-644
• 38 Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92 (06) 552-555
• 39 González-Duarte A, Norcliffe-Kaufmann L. Is ‘happy hypoxia’ in COVID-19 a disorder of autonomic interoception? A hypothesis. Clin Auton Res 2020; 30 (04) 331-333
• 40 Frontera JA, Sabadia S, Lalchan R. et al. A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City. Neurology 2021; 96 (04) e575-e586